Clinical trial
Trial of Myocet in Metastatic Breast Cancer
NCT00294996 · Sopherion Therapeutics, Industry · Unknown status
Key facts
| NCT number | NCT00294996 |
|---|---|
| Title | Trial of Myocet in Metastatic Breast Cancer |
| Official title | A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab and Paclitaxel Versus Trastuzumab and Paclitaxel for First-Line Therapy of Metastatic Breast Cancer |
| Lead sponsor | Sopherion Therapeutics, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Myocet |
| Enrollment | 363 |
| Start date | Jan 1, 2006 |
| First posted | Feb 22, 2006 |
| Last update posted | Mar 31, 2009 |
| Countries | Argentina, Canada, Germany, India, Italy, Poland, Portugal, Russia, Spain, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: